Related Experiment Video
Updated: Sep 8, 2025
10:35
Stereotactic Radiosurgery for Gynecologic Cancer
Published on: April 17, 2012
18.3K
Carbon-ion radiotherapy for urological cancers
Hitoshi Ishikawa1, Yuichi Hiroshima1, Nobuyuki Kanematsu1
1QST Hospital, National Institutes for Quantum Science and Technology, Chiba, Japan.
Summary
Carbon-ion radiotherapy offers superior dose distribution and biological effects for radioresistant tumors like prostate cancer and sarcomas. This advanced treatment is now covered by Japanese health insurance, expanding its accessibility.
Area of Science:
- Oncology
- Radiation Physics
- Medical Physics
Background:
- Carbon-ions possess high linear energy transfer, enabling superior dose distribution and enhanced biological effects compared to photons and protons.
- Radioresistant tumors, including prostate cancer, renal cell carcinoma, and retroperitoneal sarcomas, benefit from carbon-ion radiotherapy's unique radiobiological properties.
- These properties include increasing relative biological effectiveness towards the Bragg peak, reduced oxygen enhancement ratio, and decreased dependence on fractionation and cell-cycle stage.
Purpose of the Study:
- To review the characteristics, clinical outcomes, and future perspectives of carbon-ion radiotherapy for specific urological tumors.
- To highlight efforts in establishing carbon-ion radiotherapy as a standard cancer therapy through multi-institutional studies and patient registries.
- To discuss the current status of insurance coverage for carbon-ion therapy in Japan.
Main Methods:
- Review of clinical data and outcomes from carbon-ion radiotherapy treatments conducted since 1994 at the National Institute of Radiological Sciences.
- Establishment of the Japan Carbon-ion Radiation Oncology Study Group to create a patient registry and conduct prospective multi-institutional studies.
- Analysis of evidence supporting the efficacy and feasibility of carbon-ion therapy for prostate cancer and retroperitoneal sarcoma.
Main Results:
- Carbon-ion therapy has demonstrated efficacy and feasibility for prostate cancer and retroperitoneal sarcoma, leading to its coverage by the Japanese health insurance system.
- Despite previous studies showing efficacy, carbon-ion radiotherapy for renal cell cancer is not yet covered by the Japanese health insurance system.
- Accumulating evidence supports the advancement of carbon-ion radiotherapy as a viable treatment option.
Conclusions:
- Carbon-ion radiotherapy presents a promising therapeutic option for radioresistant urological tumors due to its advanced physical and biological characteristics.
- The establishment of study groups and registries facilitates the collection of evidence for broader clinical adoption and insurance coverage.
- Continued research and dissemination efforts are crucial for expanding the global use of carbon-ion radiotherapy.
